NinaMED Secures $13.75M for NiNA Wearable Neuromodulation System for Overactive Bladder
Summary
NinaMED, a newly formed Australian medical device company, has announced $13.75 million (AUD $19 million) in financing led by SPRIM Global Investments. NinaMED holds an exclusive license from Toronto-based EBT Medical to develop and commercialize the NiNA System, a non-invasive, at-home, drug-free wearable neuromodulation therapy for overactive bladder affecting 550 million people worldwide. The device targets the saphenous nerve in the upper calf and has been studied in multiple feasibility studies in the US and Canada.
Why it matters
This financing demonstrates growing investor interest in wearable peripheral neuromodulation for large patient populations with limited treatment options. Current overactive bladder therapies involve medications with systemic side effects, invasive injections, or frequent in-clinic procedures. NinaMED's at-home wearable approach could significantly improve patient adherence and quality of life while reducing healthcare system burden. The Australian headquarters with global commercial ambitions represents a growing trend of geographically diverse neurotech innovation.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial